Xenon Pharmaceuticals Inc. (XENE): Price and Financial Metrics

XENE POWR Grades

• Growth is the dimension where XENE ranks best; there it ranks ahead of 51.62% of US stocks.
• XENE's strongest trending metric is Growth; it's been moving up over the last 179 days.
• XENE ranks lowest in Stability; there it ranks in the 11th percentile.

XENE Stock Summary

• XENE's price/sales ratio is 85.98; that's higher than the P/S ratio of 97.4% of US stocks.
• Equity multiplier, or assets relative to shareholders' equity, comes in at 1.05 for Xenon Pharmaceuticals Inc; that's greater than it is for only 6.31% of US stocks.
• As for revenue growth, note that XENE's revenue has grown -42.68% over the past 12 months; that beats the revenue growth of only 3.83% of US companies in our set.
• Stocks with similar financial metrics, market capitalization, and price volatility to Xenon Pharmaceuticals Inc are NRIX, JNCE, SGMO, ATHX, and IMGN.
• XENE's SEC filings can be seen here. And to visit Xenon Pharmaceuticals Inc's official web site, go to www.xenon-pharma.com.

XENE Valuation Summary

• XENE's price/sales ratio is 39.7; this is 249.78% higher than that of the median Healthcare stock.
• Over the past 83 months, XENE's EV/EBIT ratio has gone down 20.2.
• XENE's price/sales ratio has moved up 34.4 over the prior 83 months.

Below are key valuation metrics over time for XENE.

XENE Growth Metrics

Its 5 year cash and equivalents growth rate is now at 7.93%.
• Its year over year net income to common stockholders growth rate is now at 0.79%.
• Its year over year revenue growth rate is now at 111.74%.

XENE's revenue has moved up $18,437,000 over the prior 34 months.

The table below shows XENE's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-12-31	18.437	-69.502	-77.087
2021-09-30	19.85	-61.906	-63.985
2021-06-30	18.28	-58.053	-57.507
2021-03-31	29.446	-55.765	-36.089
2020-12-31	32.166	-48.124	-28.013
2020-09-30	30.345	-15.275	-26.991

XENE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• XENE has a Quality Grade of D, ranking ahead of 7.55% of graded US stocks.
• XENE's asset turnover comes in at 0.077 -- ranking 283rd of 681 Pharmaceutical Products stocks.
• ADMP, ACUR, and ELTP are the stocks whose asset turnover ratios are most correlated with XENE.

The table below shows XENE's key quality metrics over time.